• Assembly Biosciences highlighted four clinical-stage programs, led by ABI-6250, an oral NTCP inhibitor for hepatitis D and cholestatic liver diseases.
• ABI-6250 Phase 2 start targeted for 4Q 2026 in hepatitis D; data expected 4Q 2027; PBC/PSC Phase 2 start 1Q 2027.
• HSV candidates ABI-5366 and ABI-1179 posted positive Phase 1b antiviral activity; Phase 2 initiation anticipated in 2026 under Gilead collaboration.
• Gilead deal terms include USD 100 million upfront, opt-in fees of at least USD 45 million per program, up to about USD 330 million milestones per program.
• Cash, cash equivalents, and marketable securities totaled about USD 227 million as of March 31, 2026; runway projected into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.